title: CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus.
abstract: Cytomegalovirus (CMV) infection and disease are important complications after hematopoietic stem cell transplant, particularly after transplant from alternative donors. Allogeneic cord blood transplantation (CBT) is being increasingly used, but immune recovery may be delayed. The aim of this study was to compare CMV infection in CBT with transplants from unrelated or mismatched related donors, from now on defined as alternative donors. A total of 165 consecutive transplants were divided in 2 groups: (1) alternative donors transplants (n = 85) and (2) CBT recipients (n = 80). Donor and recipient (D/R) CMV serostatus were recorded. The incidence of CMV infection, its severity, timing, and outcome were compared. Median follow-up was 257 days (1-1328). CMV infection was monitored by CMV antigenemia and expressed as CMV Ag positive cell/2 × 10(5) polymorphonuclear blood cells. There was a trend toward a higher cumulative incidence of CMV infection among CBT than alternative donor transplant recipients (64% vs 51%, P = .12). The median time to CMV reactivation was 35 days, and was comparable in the 2 groups (P = .8). The maximum number of CMV-positive cells was similar in the 2 groups (11 versus 16, P = .2). The time interval between the first and the last positive CMV antigenemia was almost 4 times longer in CBT compared with alternative donor transplants (109 vs 29 days, respectively, P = .008). The incidence of late CMV infection was also higher in CBT (62% vs 24%, P < .001). The incidence of early and late CMV infection in CBT was similar to D-/R+ alternative transplants, and higher than in D+/R+ alternative transplants: early infection, 72% in CBT versus 69% in D-/R+ alternative versus 55% in D+/R+ alternative (P = .21); and late infection, 67% in CBT versus 60% in D-/R+ alternative versus 7% in D+/R+ alternative (P < .001). Transplant-related mortality and overall survival were similar between the groups: 34% versus 36% (P = .6) and 54% versus 46% (P = .3) for alternative transplant and CBT, respectively. Longer duration and higher incidence of late CMV infection was seen in CBT patients, when compared with alternative donor transplants, whereas no difference in mortality was observed. The duration and incidence of late CMV infection were similar when D-/R+ CBT were compared with D-/R+ alternative donor transplants.
authors.affiliation: Division of Infectious Diseases, San Martino University Hospital, Genoa, Italy. m_mikulska@yahoo.com
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Mikulska
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Raiola
authors.forename: Paolo
authors.initials: P
authors.lastname: Bruzzi
authors.forename: Riccardo
authors.initials: R
authors.lastname: Varaldo
authors.forename: Silvana
authors.initials: S
authors.lastname: Annunziata
authors.forename: Teresa
authors.initials: T
authors.lastname: Lamparelli
authors.forename: Francesco
authors.initials: F
authors.lastname: Frassoni
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Tedone
authors.forename: Barbara
authors.initials: B
authors.lastname: Galano
authors.forename: Andrea
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: Claudio
authors.initials: C
authors.lastname: Viscoli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D005260:Female; D005312:Fetal Blood / Q000821:virology; D015234:HLA-A Antigens / Q000276:immunology; D015235:HLA-B Antigens / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D014019:Tissue Donors; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens